Letters by company
Accenture plc
3 letters discussing ACN. Everything written about it on this site is on its ticker page.
- Distillate Capital 2026 Q2 Letter to Investors: Momentum Distillate Capital argues that AI-linked valuations have outrun underlying free cash flow, with hyperscaler capital spending shifting profits toward semiconductor and equipment suppliers. The firm favors high-quality, low-valuation stocks, cites Accenture as a contrarian example, and warns that depreciation, stock compensation, off-balance-sheet financing, and circular AI funding can obscure earnings. 2026 Q2 ACN $113BAMZN $2.8TAVGO $1.8TGOOGL $4.2T
- Ariel Investments Portfolio Manager Letter Ariel Fund and Ariel Appreciation Fund maintained their valuation discipline despite AI-driven technology leadership, arguing that semiconductor and memory businesses remain cyclical and capital intensive. The managers cited Generac Holdings and Accenture as examples of technology-related investments that met their franchise and valuation standards, while adding several financial, insurance and industrial holdings and exiting lower-conviction positions. Q2 2026 ACN $113BGNRC $12B
- Weitz Investment Management Letter to Shareholders: Value Matters Weitz Investments has concentrated portfolios in steady earners rather than the narrow group of AI-led index winners, leaving Nvidia unowned while retaining exposure through Alphabet, Microsoft, Amazon, Meta and Oracle. The firm argues that Salesforce, Constellation Software and Accenture can benefit from enterprise AI adoption, while Danaher and Thermo Fisher retain long-term life-sciences potential despite policy disruptions. 3Q25 DHR $149BTMO $231BACN $113BAMZN $2.8T
